Cotización Aditxt - ADTX

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

0.3418

Postura de Compra

0.3418

Postura de Venta

0.3455

Volume Operado de la Acción

5,852

0.00 Rango del Día 0.00

0.31 Rango de 52 semanas 380.00

Capitalización de Mercado [m]

46.046k

Precio Anterior

0.3389

Precio de Apertura

Hora

0.3418

Última hora de negociación

06:00:48

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

4,136,850

Acciones en circulación

134,717

Rendimiento del Dividendo

Ratio Precio/Utilidad

0.00

Beneficio por acción (BPA)

-242.74

turnover

645k

Beneficio neto

-32.7M

Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantatio... Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.aditxt.com

Sede

Camden, Delaware, USA

Fundado

Aditxt Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADTX. The last closing price for Aditxt was US$0.34. Over the last year, Aditxt shares have traded in a share price range of US$ 0.31 to US$ 380.00.

Aditxt currently has 134,717 shares in issue. The market capitalisation of Aditxt is US$45,655.59 . Aditxt has a price to earnings ratio (PE ratio) of 0.00.

Form 8-K - Current report

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PR Newswire SAN DIEGO, Nov. 14, 2024 — Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially...

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social...

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.0051	-1.47016431248	0.3469	0.3789	0.31	1278221	0.34421674	CS
4	-0.5583	-62.0264415065	0.9001	0.92	0.31	2515006	0.50769957	CS
12	-25.1662	-98.6600282264	25.508	28.84	0.31	4136850	3.24457053	CS
26	-82.0582	-99.5851941748	82.4	108	0.31	3091340	24.7247893	CS
52	-141.2582	-99.7586158192	141.6	380	0.31	1976742	64.09879681	CS
156	-1823.6582	-99.9812609649	1824	45584	0.31	2178522	1027.29285792	CS
260	-8447.6582	-99.995954072	8448	45584	0.31	2278067	2455.53213874	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
WORXSCWorx Corporation	US$ 1.98 (102.04%)	16.34M
AKTSAkoustis Technologies Inc	US$ 0.1321 (51.66%)	57.77M
PETWag Group Company	US$ 0.303 (44.22%)	18.31M
ESGROEnstar Group Ltd	US$ 28.00 (40.92%)	28
CCECCapital Clean Energy Carriers Corporation	US$ 24.99 (34.72%)	11
WSBFWaterstone Financial Inc	US$ 9.00 (-40.98%)	4
TRSTriMas Corporation	US$ 15.62 (-40.79%)	3
BCAXBicara Therapeutics Inc	US$ 11.00 (-40.15%)	212
PYXSPyxis Oncology Inc	US$ 2.43 (-36.39%)	209.56k
XNCRXencor Inc	US$ 15.11 (-36.30%)	2
AKTSAkoustis Technologies Inc	US$ 0.1321 (51.66%)	57.77M
PETWag Group Company	US$ 0.303 (44.22%)	18.31M
WORXSCWorx Corporation	US$ 1.98 (102.04%)	16.34M
XTKGX3 Holdings Company Ltd	US$ 0.0775 (-13.89%)	10.83M
CRKNCrown Electrokinetics Corporation	US$ 0.9853 (25.41%)	5.59M